alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Photovoltaic Energy Harvesting

TEXTILES FOR FIRST RESPONDER 

ENSEMBLES 

First Responders need light weight, conformable power 

for communications equipment, sensors, and overall 

body-worn electronic devices. 

This requirement has been identified as a high priority by the 

Department of Homeland (DHS) Security Science and 

Technology Directorate’s First Responder Resource Group 

(FRRG).

 

DEVELOPMENT APPROACH AND IMPACT 

Silica-based solar cells are heavy and rigid. Most thin film solar 

cells have poor flex life, are not breathable, are low efficiency, 

and cannot be integrated into fabric.

The proposed solution involves the development of a 

photovoltaic (PV) fiber that can be woven into a power fabric 

and integrated on to first responder garments, shelters, and 

related equipment to provide reliable power for charging 

batteries or power electronics. 

This project will develop commercially viable, textile-integrated, 

energy-harvesting photovoltaic devices that can be fielded for 

direct DHS application. In addition, the platform technology has 

a wide range of applications for force protection across the 

United States government. 

ACCOMPLISHMENTS TO DATE 

 Phase 1. Proof of Concept / Small Scale (100 cm2)

Demonstration of OPV fabric (Completed) 

 Phase 2. Scale up of Production and Testing of OPV 

Energy Harvesting Fabric Swatches and demonstration of 

integration onto fire fighter garment. (on-going)

UPCOMING MILESTONES 

 Phase 3. Production of Limited Quantity of OPV Fabric 

Using Standard Industrial Equipment/Processes 

 Phase 4. Manufacture of Garments from OPV Energy 

Harvesting Fabric for Evaluation by Responders

PARTNERS AND PERFORMERS

 Protect The Force Inc – Jacksboro, TN Boston MA 

 University of Massachusetts-Lowell, MA 

 Textech Inc, Portland, ME

 Saunders Electronics, Portland, ME

KEY CUSTOMERS

 U.S. Customs and Border Protection

 Wildland firefighters

Contact Us: SandT.Innovation@hq.dhs.gov scitech.dhs.gov dhsscitech 

20 20 -01
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 10-1955

TORINA A. COLLIS,

Plaintiff - Appellant,

v.

BANK OF AMERICA, NATIONAL ASSOCIATION,

Defendant - Appellee.

Appeal from the United States District Court for the District of 

Maryland, at Greenbelt. Peter J. Messitte, Senior District 

Judge. (8:06-cv-01411-PJM)

Submitted: April 28, 2011 Decided: May 2, 2011

Before DAVIS, KEENAN, and WYNN, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Torina A. Collis, Appellant Pro Se. Elena D. Marcuss, 

MCGUIREWOODS, LLP, Baltimore, Maryland, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Torina A. Collis appeals the district court’s order in 

her civil action granting in part and denying in part her motion 

to reopen. We have reviewed the record and conclude there is no 

reversible error. Accordingly, we affirm for the reasons stated 

by the district court. Collis v. Bank of Am. Nat’l Ass’n, No. 

8:06-cv-01411-PJM (D. Md. July 21, 2010). We dispense with oral 

argument because the facts and legal contentions are adequately 

presented in the materials before the court and argument would 

not aid the decisional process.

AFFIRMED
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 230 Engrossed in House (EH)]

<DOC>
H. Res. 230

                In the House of Representatives, U. S.,

                                                        March 28, 2017.
    Resolved, That upon adoption of this resolution it shall be in order to 
consider in the House the joint resolution (S.J. Res. 34) providing for 
congressional disapproval under chapter 8 of title 5, United States Code, of the 
rule submitted by the Federal Communications Commission relating to ``Protecting 
the Privacy of Customers of Broadband and Other Telecommunications Services''. 
All points of order against consideration of the joint resolution are waived. 
The joint resolution shall be considered as read. All points of order against 
provisions in the joint resolution are waived. The previous question shall be 
considered as ordered on the joint resolution and on any amendment thereto to 
final passage without intervening motion except: (1) one hour of debate equally 
divided and controlled by the chair and ranking minority member of the Committee 
on Energy and Commerce; and (2) one motion to commit.
            Attest:

                                                                          Clerk.
```
§ 211.42 Design and construction features. ( a ) Any building or buildings used in the manufacture, processing, packing, or holding of a drug product shall be of suitable size, construction and location to facilitate cleaning, maintenance, and proper operations.
( b ) Any such building shall have adequate space for the orderly placement of equipment and materials to prevent mixups between different components, drug product containers, closures, labeling, in-process materials, or drug products, and to prevent contamination. The flow of components, drug product containers, closures, labeling, in-process materials, and drug products through the building or buildings shall be designed to prevent contamination.
( c ) Operations shall be performed within specifically defined areas of adequate size. There shall be separate or defined areas or such other control systems for the firm's operations as are necessary to prevent contamination or mixups during the course of the following procedures: ( 1 ) Receipt, identification, storage, and withholding from use of components, drug product containers, closures, and labeling, pending the appropriate sampling, testing, or examination by the quality control unit before release for manufacturing or packaging;
( 2 ) Holding rejected components, drug product containers, closures, and labeling before disposition;
( 3 ) Storage of released components, drug product containers, closures, and labeling;
( 4 ) Storage of in-process materials;
( 5 ) Manufacturing and processing operations;
( 6 ) Packaging and labeling operations;
( 7 ) Quarantine storage before release of drug products;
( 8 ) Storage of drug products after release;
( 9 ) Control and laboratory operations;
( 10 ) Aseptic processing, which includes as appropriate: ( i ) Floors, walls, and ceilings of smooth, hard surfaces that are easily cleanable;
( ii ) Temperature and humidity controls;
( iii ) An air supply filtered through high-efficiency particulate air filters under positive pressure, regardless of whether flow is laminar or nonlaminar;
( iv ) A system for monitoring environmental conditions;
( v ) A system for cleaning and disinfecting the room and equipment to produce aseptic conditions;
( vi ) A system for maintaining any equipment used to control the aseptic conditions.
( d ) Operations relating to the manufacture, processing, and packing of penicillin shall be performed in facilities separate from those used for other drug products for human use.
[43 FR 45077, Sept. 29, 1978, as amended at 60 FR 4091, Jan. 20, 1995]
Federal Depository Library ProgramPersistent URL Home Page      

# Target for /GPO/gpo119522 lost

The target resource for this PURL can no longer be traced. The following is a list of the targets this PURL was previously assigned to.

Powered by the Federal Depository Library Program.                A service of the U.S. Government Publishing Office.
#### Tong Yong TANG, Petitioner, v. UNITED STATES DEPARTMENT OF JUSTICE, Attorney General Gonzales, Respondent.

No. 03-40670.

United States Court of Appeals, Second Circuit.

Nov. 4, 2005.

*101Donald F. Madeo, Madeo & Fasano, New York, NY, for Petitioner.

Michelle G. Tapken, Acting United States Attorney, Mark E. Salter, Assistant United States Attorney for the District of South Dakota, Sioux Falls, SD, for Respondent.

PRESENT: MESKILL, CABRANES, and SACK, Circuit Judges.

Petitioner Tong Yong Tang (“Tang”) petitions for review from the September 3, 2003 final order of removal by the Board of Immigration Appeals (“BIA”) affirming the decision of the Immigration Judge (“IJ”) and denying his application for asylum and withholding of removal and relief under the Convention Against Torture (“CAT”). We assume the parties’ familiarity with the facts and procedural history of the case. In this appeal, Tang challenges the BIA’s determination that he failed to establish past persecution or a well-founded fear of future persecution.

Tang’s claims that he was threatened with arrest and injured by government officials on one occasion because of his father’s involvement with the Falun Gong, and that he fears arrest if returned to China because of his father’s political affiliation, do not “rise above mere harassment.” *Chen v. INS,*359 F.3d 121, 127 (2d Cir.2004). Tang’s family members, who continue to reside in China, have been questioned since the time Tang fled China, and none have been arrested or injured. *Id.*(explaining that “persecution” involves conduct that is “more than threats to life or freedom” (internal quotations omitted)). Thus, Tang has not satisfied the standard for granting asylum, and consequently cannot meet the higher standard for granting withholding of removal. *See Ramsameachire v. Ashcroft,*357 F.3d 169, 178 (2d Cir.2004). Further, as Tang has not demonstrated that he would be tortured if returned to China, his claims under the CAT fail as well. 8 U.S.C. § 208.16(c)(2); 8 C.F.R. § 208.18(a); *see also Wang v. Ashcroft,*320 F.3d 130, 133 (2d Cir.2003).

Accordingly, we deny Tang’s petition.
---

Smythe Ratcliffe LLP

7th Floor, Marine Building

355 Burrard Street

Vancouver, BC V6C 2G8



fax: 604.688.4675

telephone: 604.687.1231

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM



The Board of Directors IAS Energy, Inc.

We consent to the use of our report dated August 11, 2008
except as to note 15(c), which is as of August 18, 2008, on the financial
statements of IAS Energy, Inc. as of April 30, 2008 and 2007 that are included
in the Form 10-KSB, which is included, by reference in the Companys Form
S-8.

Smythe Ratcliffe LLP (signed)

Vancouver, Canada August 22, 2008





|Smythe Ratcliffe LLP, a British Columbia limited
      liability partnership, is a member of PKF North American Network and
      PKF International, associations of legally independent firms. | 
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | 
|

---
##### 



EXHIBIT 99 (a)

CERTIFICATION PURSUANT TO 18 U.S.C SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Northland Cable Properties Seven
Limited Partnership (the Partnership) on Form 10Q for the period ended
March 31, 2003 as filed with the Securities and Exchange Commission on the
date hereof (the Form 10-Q), I, John Whetzell, Chief Executive Officer of
Northland Communications Corporation, the General Partner, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that;



| | (1) |  | The Form 10-Q fully complies with the requirements of
Section 13 (a) or (15(d) of the Securities Exchange Act of 1934
(15 U.S.C. 78m or 78(d)); and       
| | --- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Form 10-Q fairly
presents in all material respects, the financial condition and
results of operations of the Partnership.

Date: 5-15-03

|    |  |                         |  | 
|--- |  | ----------------------- |  | 
|/s/ |  | JOHN S. WHETZELL        |  | 
|    |  | John S. Whetzell        |  | 
|    |  | Chief Executive Officer |  | 

A signed original of this written statement required by Section 906 has been
provided to Northland Cable Properties Seven Limited Partnership and will be
retained by Northland Cable Properties Seven Limited Partnership and furnished
to the Securities and Exchange Commission or its staff upon request.
§ 111.35 Under this subpart D, what records must you make and keep? ( a ) You must make and keep records required under this subpart D in accordance with subpart P of this part.
( b ) You must make and keep the following records: ( 1 ) Written procedures for fulfilling the requirements of this subpart, including written procedures for: ( i ) Calibrating instruments and controls that you use in manufacturing or testing a component or dietary supplement;
( ii ) Calibrating, inspecting, and checking automated, mechanical, and electronic equipment; and
( iii ) Maintaining, cleaning, and sanitizing, as necessary, all equipment, utensils, and any other contact surfaces that are used to manufacture, package, label, or hold components or dietary supplements;
( 2 ) Documentation, in individual equipment logs, of the date of the use, maintenance, cleaning, and sanitizing of equipment, unless such documentation is kept with the batch record;
( 3 ) Documentation of any calibration, each time the calibration is performed, for instruments and controls that you use in manufacturing or testing a component or dietary supplement. In your documentation, you must: ( i ) Identify the instrument or control calibrated;
( ii ) Provide the date of calibration;
( iii ) Identify the reference standard used including the certification of accuracy of the known reference standard and a history of recertification of accuracy;
( iv ) Identify the calibration method used, including appropriate limits for accuracy and precision of instruments and controls when calibrating;
( v ) Provide the calibration reading or readings found;
( vi ) Identify the recalibration method used, and reading or readings found, if accuracy or precision or both accuracy and precision limits for instruments and controls were not met; and
( vii ) Include the initials of the person who performed the calibration and any recalibration.
( 4 ) Written records of calibrations, inspections, and checks of automated, mechanical, and electronic equipment;
( 5 ) Backup file(s) of current software programs (and of outdated software that is necessary to retrieve records that you are required to keep in accordance with subpart P of this part, when current software is not able to retrieve such records) and of data entered into computer systems that you use to manufacture, package, label, or hold dietary supplements. ( i ) Your backup file (e.g., a hard copy of data you have entered, diskettes, tapes, microfilm, or compact disks) must be an exact and complete record of the data you entered.
( ii ) You must keep your backup software programs and data secure from alterations, inadvertent erasures, or loss; and
( 6 ) Documentation of the controls that you use to ensure that equipment functions in accordance with its intended use.
§ 516.147 Refuse to file a request for addition to the index. ( a ) If a request for addition to the index contains all of the information required by § 516.145(b), FDA shall file it, and the filing date shall be the date FDA receives the request.
( b ) If a request for addition to the index lacks any of the information required by § 516.145, FDA will not file it, but will inform the requestor in writing within 30 days of receiving the request as to what information is lacking.
UTEMPRA – Unitary Thermal Energy Management for Propulsion 

Range Augmentation

Main Author - Dr. Sourav Chowdhury, Mahle Behr Troy Inc., Principal Investigator

Co-Authors - Lindsey Leitzel, Mark Santacesaria, Mark Zima, Timothy Craig, Paul Droman, Mahle Behr Troy Inc; 

Jason Lustbader, Eugene Titov, John Rugh, National Renewable Energy Laboratory; 

Aamir Khawaja, Murali Govindarajalu, FCA US LLC.

A U.S. Department of Energy Funded Program

NREL/PR-5400-72680
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

2

Project Overview
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

3

Baseline BEV – Fiat 500e (2015 MY)

Photos by FCA
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

4

Technical Approach – UTEMPRA
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

5

Baseline Range Results
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

6

UTEMPRA System – System Schematic 1
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

7

UTEMPRA Components
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

8

UTEMPRA System Schematic Update
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

9

UTEMPRA System Modes
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

10

UTEMPRA System Modes – contd.
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

11

NREL Bench Testing with MAHLE Components

Photo by Daniel Leighton, NREL 
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

12

Projected Data - Ambient -10oC

Mode 17 ESS and Cabin Heating (NREL Model)
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

13

Projected Range Impact at Ambient -10oC

Mode 20 ESS-NTM and Cabin Heating, 40 km/h (NREL Model)
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

14

UTEMPRA Vehicle Packaging

Photos by MAHLE
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

15

Preliminary Test Data of Baseline Fiat 500e vs. UTEMPRA 

Warm up and Cool Down with Manual Control
SAE INTERNATIONAL

Copyright © SAE International. Further use or distribution is not permitted without permission from SAE

16

Conclusions and Next Steps
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1446 Manganese chloride. ( a ) Manganese chloride (MnCl2, CAS Reg. No. 7773-01-5) is a pink, translucent, crystalline product. It is also known as manganese dichloride. It is prepared by dissolving manganous oxide, pyrolusite ore (MnO2), or reduced manganese ore in hydrochloric acid. The resulting solution is neutralized to precipitate heavy metals, filtered, concentrated, and crystallized.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 186, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a nutrient supplement as defined in § 170.3(o)(20) of this chapter.
( 2 ) The ingredient may be used in infant formulas in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the act) or with regulations promulgated under section 412(a)(2) of the act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[50 FR 19165, May 7, 1985, as amended at 76 FR 59250, Sept. 26, 2011]
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1282 Dill and its derivatives. ( a ) Dill (American or European) is the herb and seeds from *Anethum graveolens* L., and dill (Indian) is the herb and seeds from *Anethum sowa,* D.C. Its derivatives include essential oils, oleoresins, and natural extractives obtained from these sources of dill.
( b ) Dill oils meet the description and specifications of the “Food Chemicals Codex,” 4th ed. (1996), pp. 122-123, which is incorporated by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the National Academy Press, Box 285, 2101 Constitution Ave. NW., Washington, DC 20055 (Internet address *http://www.nap.edu*), or may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) Dill and its derivatives are used as flavoring agents and adjuvants as defined in § 170.3(o)(12) of this chapter.
( d ) The ingredients are used in food at levels not to exceed good manufacturing practice.
( e ) [Reserved]
( f ) Prior sanctions for these ingredients different from the uses established in this section do not exist or have been waived.
[42 FR 14653, Mar. 15, 1977, as amended at 42 FR 55205, Oct. 14, 1977; 49 FR 5612, Feb. 14, 1984; 64 FR 1760, Jan. 12, 1999; 81 FR 5595, Feb. 3, 2016; 88 FR 17724, Mar. 24, 2023]
# Fourth Court of Appeals San Antonio, Texas

October 28, 2020

No. 04

- 20

- 00296

- CR

Neil Howard MCGINNIS, Appellant

v.

The STATE of Texas, App ellee

From the 451st Judicial District Court

, Kendall County, Texas

Trial Court No. 6781 Honorable Kirsten Cohoon , Judge Presiding



### O R D E R

O n August 26, 2020

, we abated this appeal and remanded the cause to the trial court to determine, inter alia, whether Appellant wanted court

- appointed counsel. As ordered, the trial court held a hearing, made findings of fact and conclusions of law, and appointed counsel to represent Appellant in this appeal. The trial court clerk and reporter each filed supplemental records. We REINSTATE this appeal on this court’s docket. Appellant’s brief i s due November 23, 2020

. See T EX

. R. A PP

. P. 38.6 (a)

.

_________________________________ Patricia O. Alvarez, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said court on this 28th day of October, 2020

.

___________________________________ MICHAEL A. CRUZ

, Clerk of Court